Stay in touch
Prime news from our network.
#read
Vfa calls for reforms for modernisation and stable financing of the healthcare system
The German Association of Research-Based Pharmaceutical Companies (vfa) sees an urgent need for action to make the German healthcare system fit for the future. In a current position paper, the association draws attention to modernisation deficits, which are particularly significant in the area of digitalisation.
08/01/2025
At the same time, the financial situation of statutory health insurance (SHI) is deteriorating with rising supplementary contributions and dwindling reimbursements. This development requires fundamental changes to prevent a downward spiral and to keep Germany competitive in an international comparison, emphasises vfa President Han Steutel. The vfa is committed to sustainable and stable financing of the SHI system and presents concrete proposals to strengthen the system in the long term. As the organisation representing the interests of research-based pharmaceutical companies in Germany, the association represents 46 leading global manufacturers and their subsidiaries and affiliates. These companies play a central role in the German pharmaceutical market and employ around 100,000 people in Germany, around 20,000 of whom work in research and development.
The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.